August 30, 2026
Cancer Vaccine Rally Meets Rate Hike Jitters
In the final week of August, U.S. stocks softened as rising odds of another Fed rate hike pressured rate‑sensitive and cyclical sectors, even as blockbuster news from Moderna’s cancer vaccine and Salesforce’s AI‑driven earnings beat powered sharp gains in healthcare and select tech names. The market is increasingly split between companies with strong growth narratives and those struggling under the weight of higher yields.